The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | PanaMa: maintenance FU/FA with or without panitumumab in mCRC
Dominik Paul Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses findings from the Phase II PanaMa trial (NCT01991873), which assessed folinic acid plus 5-fluorouracil (FU/FA) maintenance therapy with or without panitumumab in RAS wild-type metastatic colorectal cancer (mCRC). Progression-free survival (PFS), the primary endpoint, was significantly improved with the addition of panitumumab. However, long term benefits remain suboptimal. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role – Amgen; Bristol-Myers Squibb; Cor2Ed; Incyte; IQvia; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Roche; SERVIER
Research Funding – Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses – Amgen; Merck Serono; SERVIER
